Underfunded Area

The Scientist is to be commended for its considered treatment of neuroscience research funding in Job Market Sluggish For Neuroscientists by Marcia Clemmitt (Oct. 12, 1992, page 1). The article correctly points out that even though this is one of the most exciting areas of biomedical science, most fine research is underfunded. When Congress passed the Decade of the Brain resolution, hopes were justifiably raised that funding for neuroscience would finally catch up to the enormous research oppo

Written byLawrence Hoffheimer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Scientist is to be commended for its considered treatment of neuroscience research funding in Job Market Sluggish For Neuroscientists by Marcia Clemmitt (Oct. 12, 1992, page 1). The article correctly points out that even though this is one of the most exciting areas of biomedical science, most fine research is underfunded.

When Congress passed the Decade of the Brain resolution, hopes were justifiably raised that funding for neuroscience would finally catch up to the enormous research opportunities.

However, the road has not been smooth. Most of the constituency for expanded research, including professional societies, government research agencies, and voluntary health agencies, were not accustomed to working collectively. The 20 federal agencies supporting brain and behavior research were also not accustomed to cooperative action, and some were quite threatened by it. The Decade of the Brain effort lost its founder, Rep. Silvio O. Conte (R-Mass.), whose advocacy for years was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies